Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of BMS-986141 in Hepatic Impairment
NCT02985632Phase 1Withdrawn
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2017
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bms-986141 in thrombosis and coronary artery disease (CAD) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration, Area under the plasma concentration-time curve from time zero extrapolated to infinite time and 2 more. Planned start Jan 2017; status: withdrawn.
02
Drugs
bms-986141
03
Conditions
thrombosiscoronary artery disease (CAD)
Beyond the preview
Go deeper on NCT02985632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02985632.